Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-04

Study Completion Date

2032-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases

NCT05383339

Autoimmune Diseases Vasculitis Autoinflammatory Disease

RECRUITING

Immunome Project Consortium for Autoinflammatory Disorders

NCT03919110

Autoinflammatory Diseases, Hereditary

COMPLETED

Anti-nucleosome B Lymphocytes in Lupus

NCT01889654

Systemic Lupus Erythematosus With or Without Clinical Activity

TERMINATED

Molecular Diagnosis of Systemic Autoinflammatory Diseases

NCT05364294

Inflammatory Disease Genetic Disease Somatic Mutation +2 more

RECRUITING

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort

NCT02890134

Systemic Autoimmune Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autoimmune diseases group together less than a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (FAI²R: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. In addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. Consequently and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lupus Erythematosus Scleroderma Myositis Vasculitis Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients suffering from autoimmune disease

Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity.

Blood sampling

Intervention Type BIOLOGICAL

Blood will be taken in larger quantity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling

Blood will be taken in larger quantity.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),
* Patients with atypical presentations of documented or probable systemic autoimmune diseases,
* Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).